CTLA4 and viral infectious disease: Future studies should also incorporate more well-known inhibitory molecules, such as LAG-3, GITR, PD-1, and CTLA-4, whose alterations are commonly associated with viral infections and COVID-19, such as LAG-3, GITR, PD-1, or CTLA-4 (69).